The effect of intravitreal anti-VEGF on the pigment epithelial detachment in eyes with the exudative type of age-related macular degeneration

Seminars in Ophthalmology

Volumn 30, Issue 1, 2015, Pages 6-10

  Kalouda, Pelagia ^a   Anastasakis, Anastasios ^a   Tsika, Chrysanthi ^a   Miltiadis Tsilimbaris, K ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Choroidal neovascularization; Optical coherence tomography; Ranibizumab; VEGF

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT ASSESSMENT; QUALITATIVE ANALYSIS; RETINA DETACHMENT; RETROSPECTIVE STUDY; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PIGMENT EPITHELIUM; RETINAL DETACHMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84918819968     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.807852     Document Type: Article

References (25)

1. Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment: major review. Survey of Ophthalmology 2007;52:227-243.
2. Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age related macular degeneration: classification and therapeutic options. Seminars in Ophthalmology 2011;26(3):198-208.
3. Ladas ID, Kotsolis AI, Rouvas AA, et al. Efficacy of photodynamic therapy in the management of occult choroidal neovascularization associated with serous pigment epithelium detachment. Ophthalmologica 2007; 221(5):313-319.
4. Chan C, Abraham P, Meyer C, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 2010;30:203-211.
5. Chiang A, Chang L, Yu F, et al. Predictors of anti-VEGF associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008;28:1265-1269.
6. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19: 361-372.
7. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multi-dose study. Ophthalmology 2006;113:642e1-642e4.
8. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularisation with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120: 338-346.
9. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macu-lar degeneration. Ophthalmic Surg Lasers Imaging 2005;36: 331-335.
10. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103: 1260-1270.
11. Plainis S, Tzatzala P, Orphanos Y, Tsilimparis MK. A modified ETDRS visual acuity chart for European-wide use. Optometry and Vision Science 2007;84(7):647-653.
12. Parodi MB, Iacono P, Papayannis A, et al. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. American Journal of Ophthalmology 2013;155(1):103-108.e2.
13. Ritter M, Bolz M, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye 2010;24: 962-968.
14. Khetpal V, Heimmel MR, Rao S, et al. Resolution of retinal pigment epithelial detachment associated with exudative age-related macular degeneration following intravitreal ranibizumab therapy. Acta Ophthalmologica 2009;87(1):115-116.
15. Loukianou E, Kisma N, Hamilton R. Complete resolution of a giant pigment epithelial detachment secondary to exudative age-related macular degeneration after a single intravitreal ranibizumab injection: results documented by OCT. Ophthalmology 2010;1:110-113.
16. Aggio FB, Farah ME, Melo GB. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Acta Ophthalmologica Scandinavica 2006;84(5):713-714.
17. Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 2009;23:2163-2168.
18. Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clinical Ophthalmology 2010;4:369-374.
19. Joeres S, Kaplowitz K, Brubaker JW, et al. Quantitative comparison of optical coherence tomography after pegap-tanib or bevacizumab in neovascular age-related macular degeneration. Ophthalmology 2008;115(2):347-354.
20. Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina. 2010;430(9): 1420-1425.
21. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007;27(4):445-450.
22. Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:779-784.
23. Introini U, Torres Gimeno A, Scotti F, et al. Vascularised retinal pigment epithelial detachment in age-related macu-lar degeneration: treatment and RPE tear incidence. Graefes Arch Clin Exp Ophthalmol Sep 2012; 250(9):1283-92.
24. Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye 2011;25:1034-1038.
25. Baba T, Kitahashi M, Kubota-Taniai M, et al. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40. Ophthalmologica 2012;228:102-109.